Positions

Overview

  • I am dual-trained in both Medical Hematology/Oncology and Clinical Pharmacology and Pharmacogenomics at the University of Chicago. My specialty training allowed me to develop expertise in clinical trial design, pharmacokinetics (PK)/pharmacodynamics (PD) analysis, drug development, and patient care. In September 2015, I joined the faculty at the University of Alabama at Birmingham as an Assistant Professor of Medicine. My focus remains in highly aggressive women’s malignancies (i.e. triple-negative and HER2+ breast cancer as well as high-grade serous ovarian cancer) and early-phase clinical trial design. In this role, I serve as a clinician-scientist helping laboratory-based scientist translate laboratory findings to the clinical setting by designing trials.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 TrialJAMA Oncology.  6:676-684. 2020
    2020 Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology 2020
    2020 MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2–positive and/or hormone receptor–negative breast cancers in the I-SPY 2 trialJournal of Clinical Oncology.  38:1059-1069. 2020
    2019 Single-Arm Phases 1 and 2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Recurrent Platinum-Resistant Ovarian CarcinomaJAMA Oncology.  5:1141-1149. 2019
    2018 Future Developments in Neoadjuvant Therapy for Triple-Negative Breast CancerSurgical Clinics of North America.  98:773-785. 2018
    2017 MicroRNA-200c and microRNA- 141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancerBreast Cancer Research.  19. 2017
    2016 A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancerSpringerPlus.  5. 2016
    2015 Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinomaGynecologic Oncology.  138:656-662. 2015

    Chapter

    Year Title Altmetric
    2014 Chemotherapy and/or targeted therapies for advanced endometrial cancer: Time to rethink?.  59-68. 2014

    Research Overview

  • Breast Cancer
    Ovarian Cancer
    Developmental Therapeutics
    Translational Research
  • Principal Investigator On

  • Private Grant  awarded by Pfizer Pharmaceuticals 2019 - 2025
  • Private Grant  awarded by CALITHERA BIOSCIENCES INC 2019 - 2024
  • TBCRC 050 UAB 17112-A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer  awarded by Johns Hopkins University 2019 - 2024
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • TBCRC 049 UAB 1794: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer  awarded by Johns Hopkins University 2018 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2018 - 2023
  • Private Grant  awarded by ELI LILLY AND COMPANY 2019 - 2023
  • TBCRC 040: Pathologic Response Evaluation & Detection In Circulating Tumor DNA (PREDiCT DNA)  awarded by Johns Hopkins University 2017 - 2022
  • PARP Inhibitors: A Novel Mechanism to Overcome Resistance in Aggressive HER2+Breast Cancers  awarded by V FOUNDATION FOR CANCER RESEARCH 2018 - 2021
  • Private Grant  awarded by TESARO, INC. 2018 - 2021
  • A New Paradigm: Using PARP Inhibitors to Treat HER2+ Breast Cancer  awarded by Komen (Susan G.) Breast Cancer Foundation 2018 - 2021
  • UAB 1761: A Randomized, Placebo-Controlled, Double-Blind, Phase II trial of Nanoparticle Albumin-Bound Paclilaxel (Nab-Paclilaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple Negative Breast Cancer.  awarded by University of Chicago 2017 - 2021
  • Private Grant  awarded by Genentech 2016 - 2021
  • Private Grant  awarded by TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM 2018 - 2021
  • Private Grant  awarded by TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM 2018 - 2021
  • Private Grant  awarded by CASCADIAN THERAPEUTICS 2016 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2018 - 2021
  • UAB 18106:OXEL: A pilot study of immune checkpoint or capecitabine or combination therapy as adjuvant therapy for triple negative breast cancer with residual disease following neoadjuvant chemotherapy  awarded by Georgetown University 2019 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2019 - 2021
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2019 - 2020
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2018 - 2020
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2019 - 2020
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE 2018 - 2020
  • TBCRC 037 UAB 1644:A Trial of Endocrine Response In Women with Invasive Lobular Breast Cancer.  awarded by University of Pittsburgh 2016 - 2020
  • Private Grant  awarded by CALITHERA BIOSCIENCES INC 2017 - 2019
  • Private Grant  awarded by GlaxoSmithKline 2017 - 2019
  • Investigator On

  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2019 - 2027
  • Identifying a New Biological Target for Breast Cancer Therapy That Contributes to Disparities for African-American Women  awarded by National Cancer Institute/NIH/DHHS 2020 - 2025
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University 2020 - 2025
  • Private Grant  awarded by ARCUS BIOSCIENCES INC 2020 - 2025
  • Private Grant  awarded by MERCK SHARP & DOHME CORP 2020 - 2025
  • Private Grant  awarded by TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM 2020 - 2025
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2019 - 2025
  • TBCRC -AURORA US: A Prospective Biospecimen Repository in Metastic Breast Cancer  awarded by Johns Hopkins University 2020 - 2025
  • Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer  awarded by National Cancer Institute/NIH/DHHS 2020 - 2024
  • Private Grant  awarded by ELI LILLY AND COMPANY 2019 - 2024
  • TBCRC 042 UAB 1905: A Randomized, Phase II, Window-of-Opportunity Trial of Ruxolitinib in Patients with High Risk and Premalignant Breast Conditions  awarded by Johns Hopkins University 2019 - 2024
  • Private Grant  awarded by PROTEOGENOMICS RESEARCH INSTITUTE FOR SYSTEMS MEDICINE 2019 - 2024
  • Personalizing Immunotherapy in HER2+ Breast Cancer through Quantitative Imaging  awarded by National Cancer Institute/NIH/DHHS 2020 - 2024
  • A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination with Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), In Patients with Her2-Positive Metastatic Breast Cancer who have Progressed on Prior Trastuzumab and Pertuzumab: The "AVIATOR” Study  awarded by Johns Hopkins University 2019 - 2024
  • TBCRC 048 UAB 1846: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes  awarded by Johns Hopkins University 2018 - 2023
  • UAB17127:A phase Ib trial of fulvestrant, palbociclib (CDK4/6 inhibitor) and erdafitinib (JNJ- 42756493, pan-FGFR tyrosine kinase inhibitor) in ER+/HER2–/FGFR-amplified metastatic breast cancer (MBC)  awarded by VANDERBILT UNIVERSITY 2018 - 2023
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2019 - 2023
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS 2019 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2020 - 2023
  • Private Grant  awarded by MERSANA THERAPEUTICS 2020 - 2023
  • XUAB 17109-TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progression  awarded by Johns Hopkins University 2018 - 2023
  • Utilizing microRNA-146a to Block Triple-Negative Breast Cancer Cell Colonization  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • UAB 1430 - A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 inhibitor, in Combination with Anastrozole in Women with Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer  awarded by Washington University 2019 - 2021
  • Private Grant  awarded by INCYTE CORPORATION 2019 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2017 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2018 - 2021
  • Private Grant  awarded by EMD SERONO 2016 - 2021
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • UAB 1428 – A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer (HOG Trial)  awarded by HOOSIER CANCER RESEARCH NETWORK 2019 - 2020
  • UAB 1643- A Randomized Phase II Trial of Fulvestrant With or Without Ribociclib After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer  awarded by Columbia University 2016 - 2020
  • TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progession  awarded by Duke University 2018 - 2020
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2020
  • Private Grant  awarded by INCYTE CORPORATION 2015 - 2020
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker  awarded by Johns Hopkins University 2014 - 2019
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS 2018 - 2019
  • Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect  awarded by University of Wisconsin-Madison 2016 - 2019
  • XUAB 1769: Phase lb 9cUAB30 In Early Stage Breast Cancer to Evaluate Biologic Effect (Cost Reimbursable)  awarded by University of Wisconsin-Madison 2016 - 2019
  • Private Grant  awarded by Pfizer Pharmaceuticals 2017 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2019
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2015 - 2019
  • Private Grant  awarded by ELI LILLY AND COMPANY 2016 - 2019
  • TBCRC 026/UAB 1367: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer (ML28190)  awarded by Johns Hopkins University 2014 - 2019
  • Private Grant  awarded by ELI LILLY AND COMPANY 2018 - 2019
  • Private Grant  awarded by Genentech 2018 - 2019
  • Private Grant  awarded by Genentech 2018 - 2019
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS 2018 - 2019
  • Utilizing Multiomic Advanced Diagnostics to Identify Palbociclib Response Predictors and a Post-treatment Multiomic Signature for Patients with ER+/HER2- Metastatic Breast Cancer  awarded by THE SIDE-OUT FOUNDATION 2017 - 2019
  • Private Grant  awarded by INNOCRIN PHARMACEUTICALS, INC. 2016 - 2019
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE 2012 - 2019
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION 2015 - 2019
  • TBCRC 036 (UAB 1366): Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab + Pertuzumab, or Combination Trastuzumab + Lapatinib  awarded by Lineberger Comprehensive Care Center 2014 - 2019
  • TBCRC 033 UAB 1568: A Randomized Phase II study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage 1 HER2-Positive Breast Cancer (ATEMPT Trial)  awarded by Dana-Farber Cancer Institute 2015 - 2018
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS 2016 - 2018
  • Private Grant  awarded by TESARO, INC. 2016 - 2018
  • TBCRC 035 UAB 15114: Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II Study with Pharmacodynamics Markers (TBCRC 35)  awarded by Johns Hopkins University 2016 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2016 - 2018
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2018
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2018
  • Education And Training

  • Doctor of Medicine, University of South Alabama 2008
  • Bachelor of Science or Mathematics in Biomedical Sciences, Auburn University 2004
  • Tulane University, Internship 2009
  • Baptist Health System, Residency 2011
  • University of Chicago, Postdoctoral Fellowship 2015
  • University of Chicago, Postdoctoral Fellowship 2014
  • Full Name

  • Erica Stringer-Reasor